BioPharmCatalyst ✓

@BPharmCatalyst · Solana Beach, CA · joined 12 Jul 2009

FDA catalyst calendar, newsletters, and more. We do not provide investment advice or recommendations. #biotech #stocks

31 050Followers

234Following

12 675Posts total

20.6KViews on collected posts

Neueste Beiträge

BioPharmCatalyst ✓@BPharmCatalyst15 Sep

$CNTB announced Phase 2 Seabreeze STAT rademikibart asthma data, showing significant Day 7 post-bronchodilator FEV1 improvement versus placebo and a non-significant 66% drop in 28-day treatment failure with placebo-like safety; COPD exacerbation results are expected later this h

1.7K views · 1 likes · 0 reposts · 0 replies Open on X →

BioPharmCatalyst ✓@BPharmCatalyst14 Sep

$CLLS announced a strategic pivot toward in vivo gene-editing programs, focusing resources onHEAL-101 for APOC3 in severe hypertriglyceridemia andHEAL-201 for PCSK9 in severe hypercholesterolemia, with initial Phase 1 readouts expected in H2 2027 and H1 2028, respectively, while

1.9K views · 3 likes · 1 reposts · 0 replies Open on X →

BioPharmCatalyst ✓@BPharmCatalyst14 Sep

$BFRI announced that the FDA has approved the Company's sNDA for Ameluz (aminolevulinic acid hydrochloride) topical gel, 10%, in combination with photodynamic therapy using the BF-RhodoLED lamp series, for the treatment of superficial Basal Cell Carcinoma (sBCC) in adults. 1.9K views · 2 likes · 1 reposts · 0 replies Open on X →

BioPharmCatalyst ✓@BPharmCatalyst14 Sep

$DFTX reported its second positive Phase 3 GAD study for DT120 ODT, with Panorama meeting the Week 12 HAM-A primary endpoint at the 100 µg dose with a 5.1-point placebo-adjusted improvement and rapid onset by Day 2. $SCNI $CAPR $CLLS $CRBP $ARMP $DFTX $DERM $EDSA $XRTX $SLS

1.8K views · 2 likes · 0 reposts · 0 replies Open on X →

BioPharmCatalyst ✓@BPharmCatalyst11 Sep

$SRRK announced that the FDA has approved ISEMBYLD (apitegromab-mstn) for the treatment of spinal muscular atrophy (SMA) in adults and children two years of age and older who are currently receiving a survival motor neuron 2 (SMN2)-targeted treatment. https://t.co/SlAXFvfbkO 2.4K views · 6 likes · 0 reposts · 0 replies Open on X →

BioPharmCatalyst ✓@BPharmCatalyst6 Apr

@BPharmCatalyst $SILO is $.54 in AH from $.35 on patent news! 🚀 Discussed in the podcast. 369 views · 0 likes · 0 reposts · 0 replies Open on X →

BioPharmCatalyst ✓@BPharmCatalyst25 Mar

The "two-trial dogma" is over. 🧬 The FDA's new one-pivotal-trial shift is the new default for 2026, and it’s rewriting trial timelines and cash runways. In biotech, this isn't just a rule change—it's a survival metric. Full breakdown with John & @SheffStation : 🎧listen here: h

10.5K views · 18 likes · 9 reposts · 1 replies Open on X →

Im Vergleich zu Konten gleicher Größe

5 Beiträge aus den letzten 90 Tagen, verglichen mit der Größenklasse 10K–100K Follower. wird weit gezeigt, aber nur wenige dieser Zuschauer reagieren.

Medianaufrufe1 892dieses Konto924Median für 10K–100K

Reichweite, %6.09%dieses Konto3.62%Median für 10K–100K

Interaktion, %0.15%dieses Konto1.52%Median für 10K–100K

Kennzahl	Dieses Konto	Median für 10K–100K	Verhältnis
Medianaufrufe pro Beitrag	1 892	924	2.05×
Reichweite (Aufrufe ÷ Follower)	6.09%	3.62%	1.68×
Interaktionsrate	0.15%	1.52%	0.10×

Weitere Konten dieser Größe → Mit einem anderen Konto vergleichen → Wie diese Vergleichswerte entstehen →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

10.5K25 Mar

3696 Apr

2.4K11 Sep

1.8K14 Sep

1.9K

1.7K15 Sep

Last 7 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.29%25 Mar

0.00%6 Apr

0.25%11 Sep

0.11%14 Sep

0.16%

0.21%

0.06%15 Sep

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.

What the audience does

Likes60.4%32 in total

Reposts20.8%11 in total

Replies1.9%1 in total

Quotes5.7%3 in total

Bookmarks11.3%6 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Neueste Beiträge

Im Vergleich zu Konten gleicher Größe

Growth & engagement

Views per post

Engagement rate per post

What the audience does

Ähnliche Konten